Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18795129 | 0.81 | TDP1 (0.48) | ALDH1A1MAPTLMNARXFP1GAA | |
| SCHEMBL27946755 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MAPTGLAHPGDACHE | |
| SCHEMBL18819816 | 0.79 | TDP1 (0.52) | ALDH1A1MAPTLMNANPSR1SMN1; SMN2 | |
| SCHEMBL7891555 | 0.78 | ALDH1A1 (0.54) | ALDH1A1MAPTGLAHPGDACHE | |
| SCHEMBL2015910 | 0.78 | ALDH1A1 (0.48) | ALDH1A1MAPTGLAHPGDACHE | |
| SCHEMBL28678460 | 0.78 | ALDH1A1 (0.47) | ALDH1A1MAPTGLAHPGDACHE | |
| SCHEMBL10041689 | 0.77 | MAPT (0.41) | ALDH1A1MAPTGLAHPGDACHE | |
| SCHEMBL3661878 | 0.77 | ALDH1A1 (0.53) | ALDH1A1MAPTGLAHPGDACHE | |
| SCHEMBL29956438 | 0.77 | ALDH1A1 (0.47) | ALDH1A1MAPTGLAHPGDACHE | |
| SCHEMBL29956188 | 0.77 | ALDH1A1 (0.53) | ALDH1A1MAPTGLAHPGDACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115578-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) | 2025-04-10 | — | — | US | disclosed |
| EP-4455130-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | Chengdu Kanghong Pharmaceutical Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| US-20240101562-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME | HOLOSMEDIC (KR) | 2024-03-28 | — | — | US | disclosed |
| WO-2023138599-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | 成都康弘药业集团股份有限公司 | 2023-07-27 | — | — | WO | disclosed |
| CN-116462662-A | Aromatic ring Nav1.8 inhibitor and application thereof | 成都康弘药业集团股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-108395456-A | organic metal iridium complex and simple synthesis method and application thereof | 辅仁大学学校财团法人辅仁大学 | 2018-08-14 | — | — | CN | disclosed |
| US-9073863-B2 | Cyanoquinoline compounds having activity in correcting mutant-CFTR processing and increasing ion transport and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-07 | — | — | US | disclosed |
| WO-2014207213-A1 | NOVEL INHIBITORS OF PROTEIN KINASE C EPSILON SIGNALING | MEDIZINISCHE UNIVERSITÄT INNSBRUCK (AT) | 2014-12-31 | — | — | WO | disclosed |
| US-20140296215-A1 | Cyanoquinoline Compounds Having Activity in Correcting Mutant-Cftr Processing and Increasing Ion Transport and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2012166654-A1 | CYANOQUINOLINE COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR PROCESSING AND INCREASING ION TRANSPORT AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-06 | — | — | WO | disclosed |
| US-6420375-B1 | ANTITUMOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-0974584-A1 | FUSED RING COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-01-26 | — | — | EP | disclosed |
| CN-1043644-C | Process for preparing (1H-tetrazol-5-yl) tetrazolo [1,5-a] quinolines and naphthyridines | MERRELL DOW PHARMA (US) | 1999-06-16 | — | — | CN | disclosed |
| EP-0751945-B1 | PROCESS FOR PREPARING (1H-TETRAZOL-5-yl)TETRAZOLO 1,5-a] QUINOLINES AND NAPHTHYRIDINES | MERRELL PHARMA INC (US) | 1998-07-01 | — | — | EP | disclosed |
| CN-1144527-A | Process for preparing (1H-tetrazol-5-yl) tetrazolo [1,5-a] quinolines and naphthyridines | MERRELL DOW PHARMA (US) | 1997-03-05 | — | — | CN | disclosed |
| EP-0751945-A1 | PROCESS FOR PREPARING (1H-TETRAZOL-5-yl)TETRAZOLO 1,5-a] QUINOLINES AND NAPHTHYRIDINES | MERRELL PHARMACEUTICALS INC. (US) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995026348-A1 | PROCESS FOR PREPARING (1H-TETRAZOL-5-yl)TETRAZOLO [1,5-a] QUINOLINES AND NAPHTHYRIDINES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-10-05 | — | — | WO | disclosed |
| EP-0120484-B1 | (1H-TETRAZOL-5-YL)TETRAZOLO (1,5-A)-QUINOLINES AND RELATED COMPOUNDS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-04-22 | — | — | EP | disclosed |
| US-4496569-A | Antiallergic (1H-tetrazol-5-yl)tetrazolo[1,5-a]quinolines and derivatives thereof | THE DOW CHEMICAL COMPANY (US) | 1985-01-29 | — | — | US | disclosed |
| EP-0120484-A1 | (1H-tetrazol-5-yl)tetrazolo (1,5-a)-quinolines and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1984-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101562-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME | SLC11A2, ABCC1, TSG101 | ALDH1A1 3381/4885MAPT 4225/4885GLA 3389/4885 |
| US-20140296215-A1 | Cyanoquinoline Compounds Having Activity in Correcting Mutant-Cftr Processing and Increasing Ion Transport and Uses Thereof | CFTR, SLC47A1, SLC47A2 | ALDH1A1 3445/4885MAPT 4861/4885GLA 4189/4885 |
| US-20250115578-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | SCN8A, SCN10A, SCN7A | ALDH1A1 3194/4885MAPT 1605/4885GLA 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.